P-191Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND). (2nd July 2019) - Aparicio, J; Virgili, A; Capdevila, J; Muñoz Boza, F; Álvarez, R; Bosch, C; Cámara, J; Fernandez-Martos, C; Fernandez-Plana, J; Gallego, J; Gallego, R; Hernández-Yagüe, X; et al.